Randomized Trial of Nicotine Inhaler for Pregnant Smokers.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Smoking during pregnancy is a serious public health problem in need of better treatments.

However, the nicotine inhaler may have advantages over other NRTs as it replicates some of the sensory effects of smoking.

Who Took Part

By PubMed's age tags, the people studied were infants, women only.

Throughout treatment, the researchers assessed tobacco exposure biomarkers, cessation rates, and adverse events.

The researchers compared treatment groups on these measures using t-tests, Fisher's exact tests, and multivariate linear and logistic regression.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

The researchers conducted a randomized, double-blind, placebo-controlled trial of the nicotine inhaler for smoking cessation during pregnancy.

The researchers also obtained information on birth outcomes.

What Was Measured

PubMed files the paper under topics including Nebulizers and Vaporizers, Nicotine, Premature Birth, Smokers, Smoking, Smoking Cessation and Tobacco Use Cessation Devices.

The authors tagged it with the keywords nicotine inhaler, pregnancy and preterm delivery.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (American journal of obstetrics & gynecology MFM), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.